Paper15054565
Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M and 5 others. Eur J Clin Pharmacol, 2004. Cited by 61 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Papers, record 15054565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15054565
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aryl Hydrocarbon Hydroxylases | Major topic |
| Cytochrome P-450 Enzyme System | Major topic |
| Hydroxylation | Major topic |
| Phenprocoumon | Major topic |
| Antibodies, Monoclonal | |
| Anticoagulants | |
| Biotransformation | |
| Catalysis | |
| Cytochrome P-450 CYP2C19 | |
| Cytochrome P-450 CYP2C8 | |
| Cytochrome P-450 CYP2C9 | |
| Cytochrome P-450 CYP3A | |
| Drug Therapy, Combination | |
| Enzyme Inhibitors | |
| Forecasting | |
| Gene Expression | |
| Humans | |
| Isomerism | |
| Microsomes, Liver | |
| Mixed Function Oxygenases | |
| Recombinant Proteins | |
| Troleandomycin |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10,771,452 | Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. | Br J Clin Pharmacol | 2000 | https://conductscience.org/library/papers/10771452 | PubMed |
| 2 | 8,723,744 | Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. | Drug Metab Dispos | 1996 | https://conductscience.org/library/papers/8723744 | PubMed |
| 3 | 10,821,163 | Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. | Xenobiotica | 2000 | https://conductscience.org/library/papers/10821163 | PubMed |
| 4 | 2,229,265 | Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon and its metabolites, warfarin and acenocoumarol, by ultrafiltration and high-performance liquid chromatography. | J Chromatogr | 1990 | https://conductscience.org/library/papers/2229265 | PubMed |
| 5 | 14,209,971 | THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. | J Biol Chem | 1964 | https://conductscience.org/library/papers/14209971 | PubMed |
| 6 | 11,157,645 | Hemorrhagic complications of anticoagulant treatment. | Chest | 2001 | https://conductscience.org/library/papers/11157645 | PubMed |
| 7 | 8,873,220 | The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. | Pharmacogenetics | 1996 | https://conductscience.org/library/papers/8873220 | PubMed |
| 8 | 7,773,301 | Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. | Pharmacogenetics | 1995 | https://conductscience.org/library/papers/7773301 | PubMed |
| 9 | 9,526,963 | Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. | Thromb Res | 1997 | https://conductscience.org/library/papers/9526963 | PubMed |
| 10 | 11,038,154 | Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. | Drug Metab Dispos | 2000 | https://conductscience.org/library/papers/11038154 | PubMed |
| 11 | 9,920,790 | Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. | Biochem Biophys Res Commun | 1999 | https://conductscience.org/library/papers/9920790 | PubMed |
| 12 | 3,490,277 | The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat. | Biochim Biophys Acta | 1986 | https://conductscience.org/library/papers/3490277 | PubMed |
| 13 | 388,439 | Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. | Proc Natl Acad Sci U S A | 1979 | https://conductscience.org/library/papers/388439 | PubMed |
| 14 | 8,365,690 | Concentrations of phenprocoumon in serum and serum water determined by high-performance liquid chromatography in patients on oral anticoagulant therapy. | Haemostasis | 1993 | https://conductscience.org/library/papers/8365690 | PubMed |
| 15 | 12,487,725 | In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. | Xenobiotica | 2002 | https://conductscience.org/library/papers/12487725 | PubMed |
| 16 | 7,720,520 | Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. | Drug Metab Dispos | 1995 | https://conductscience.org/library/papers/7720520 | PubMed |
| 17 | 9,822,057 | Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. | Chest | 1998 | https://conductscience.org/library/papers/9822057 | PubMed |
| 18 | 15,128,047 | Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. | Pharmacogenetics | 2004 | https://conductscience.org/library/papers/15128047 | PubMed |
| 19 | 3,621,786 | The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans. | Clin Pharmacol Ther | 1987 | https://conductscience.org/library/papers/3621786 | PubMed |
| 20 | 10,793,325 | Inhibition of phenprocoumon anticoagulation by carbamazepine. | Eur Neuropsychopharmacol | 2000 | https://conductscience.org/library/papers/10793325 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36,208,621 | Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study. | Thromb Haemost | 2023 | https://conductscience.org/library/papers/36208621 | PubMed |
| 33,638,977 | The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. | Eur Heart J Cardiovasc Pharmacother | 2022 | https://conductscience.org/library/papers/33638977 | PubMed |
| 31,835,701 | Influence of Selected Carbon Nanostructures on the CYP2C9 Enzyme of the P450 Cytochrome. | Materials (Basel) | 2019 | https://conductscience.org/library/papers/31835701 | PubMed |
| 30,830,337 | Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement. | Metabolomics | 2017 | https://conductscience.org/library/papers/30830337 | PubMed |
| 29,283,396 | Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. | J Pers Med | 2017 | https://conductscience.org/library/papers/29283396 | PubMed |
| 24,324,947 | VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients. | J Stroke | 2013 | https://conductscience.org/library/papers/24324947 | PubMed |
| 23,919,835 | Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. | Br J Clin Pharmacol | 2014 | https://conductscience.org/library/papers/23919835 | PubMed |
| 23,673,224 | Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code. | Bioorg Med Chem | 2013 | https://conductscience.org/library/papers/23673224 | PubMed |
| 23,519,598 | Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. | Clin Pharmacokinet | 2013 | https://conductscience.org/library/papers/23519598 | PubMed |
| 21,452,031 | Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. | Eur J Clin Pharmacol | 2011 | https://conductscience.org/library/papers/21452031 | PubMed |
| 21,110,013 | Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. | Eur J Clin Pharmacol | 2011 | https://conductscience.org/library/papers/21110013 | PubMed |
| 20,981,234 | Pharmacogenetics of anticoagulants. | Hum Genomics Proteomics | 2010 | https://conductscience.org/library/papers/20981234 | PubMed |
| 19,641,912 | Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease. | Eur J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19641912 | PubMed |
| 19,082,874 | Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. | Pharm Res | 2009 | https://conductscience.org/library/papers/19082874 | PubMed |
| 18,758,764 | Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. | Eur J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18758764 | PubMed |
| 18,698,879 | Pharmacogenetics of oral anticoagulants: a basis for dose individualization. | Clin Pharmacokinet | 2008 | https://conductscience.org/library/papers/18698879 | PubMed |
| 17,318,526 | Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. | Eur J Clin Pharmacol | 2007 | https://conductscience.org/library/papers/17318526 | PubMed |
| 16,847,664 | Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. | Eur J Clin Pharmacol | 2006 | https://conductscience.org/library/papers/16847664 | PubMed |
| 16,372,822 | Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. | Clin Pharmacokinet | 2005 | https://conductscience.org/library/papers/16372822 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP19A1 | 1,588 | PubTator's text mining | https://conductscience.org/library/genes/1588 | NCBI Gene |
| CYP2C18 | 1,562 | PubTator's text mining | https://conductscience.org/library/genes/1562 | NCBI Gene |
| CYP2C19 | 1,557 | PubTator's text mining | https://conductscience.org/library/genes/1557 | NCBI Gene |
| CYP2C8 | 1,558 | PubTator's text mining | https://conductscience.org/library/genes/1558 | NCBI Gene |
| CYP2C9 | 1,559 | PubTator's text mining | https://conductscience.org/library/genes/1559 | NCBI Gene |
| CYP3A4 | 1,576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
| CYP4F3 | 4,051 | PubTator's text mining | https://conductscience.org/library/genes/4051 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15054565
GET https://conductscience.org/api/papers/v1/15054565/references?page=2